All In Biotech

Drug Trial Radar · NCT05944562

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Phase I Study With an Expansion Cohort of Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Actual

Start

Jan 9, 2024

Primary completion

Feb 28, 2027

Study completion Jan 31, 2029

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Novartis; The Foundation for Barnes-Jewish Hospital; Swim Across America; Daniel E. Corbin Jr. Lymphoma Fund
First posted
Jul 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The hypotheses of this study are that single agent DZR123 will be safe and well tolerated in patients with advanced (stage IB-IVB) mycosis fungoides (MF)/Sézary syndrome (SS) who have had at least one prior systemic therapy, and that in these patients, DZR123 will demonstrate efficacy and be worth of further study.

Conditions

  • Mycosis Fungoides
  • Sezary Syndrome
  • Mycosis Fungoides/Sezary Syndrome

Interventions

  • TulmimetostatDrug

    Patients should take DZR123 at approximately the same time every morning in a fasted state (no food for 2 hours prior and 1 hour following DZR123 dosing). Each dose of DZR123 should be taken with a glass of water and consumed over as short a time as possible.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and grades of treatment-emergent adverse events (TEAE)Time frame: From start of treatment through 30 days after completion of treatment (estimated to be 13 months)
  2. Rate of treatment discontinuation due to treatment-emergent adverse events (TEAE)Time frame: From start of treatment through 30 days after completion of treatment (estimated to be 13 months)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.